Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events

Stopped early

Conditions studied: Acute Myeloid Leukemia in Remission

In brief

Prospective determination of the clinical utility of measurable residual disease (MRD) testing for relapse and survival of patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (alloHCT).

Key facts

Study ID

NCT05224661

Run by

Center for International Blood and Marrow Transplant Research

People needed

303

Starts

2022-08-26

Expected to finish

2025-12-12

Last updated by the study team

2026-06-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Provision of signed and dated informed consent form
• Stated willingness to comply with all study procedures and availability for the duration of the study
• Aged at least 18 years old at time of consent
• Diagnosed with AML, in complete remission
• Complete remission (CR) definition per local institutional criteria
• CR with incomplete hematologic recovery (CRi) is not an exclusion criterion
• MRD positivity is not an exclusion criterion
• Undergoing alloHCT
• Has a diagnostic AML specimen available

You may not qualify if…

• Diagnosis of acute promyelocytic leukemia
• Prior alloHCT

Where it is running

• City of Hope — Duarte, California, United States
• University of California, San Francisco — San Francisco, California, United States
• Stanford University — Stanford, California, United States
• University of Colorado — Aurora, Colorado, United States
• University of Miami — Miami, Florida, United States
• H. Lee Moffitt Cancer Center — Tampa, Florida, United States
• Northside Hospital — Atlanta, Georgia, United States
• University of Chicago Medicine — Chicago, Illinois, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Roswell Park Comprehensive Cancer Center — Buffalo, New York, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• New York Presbyterian / Weill Cornell Medical Center — New York, New York, United States
• Levine Cancer Institute — Charlotte, North Carolina, United States
• Cleveland Clinic — Cleveland, Ohio, United States
• The Ohio State University Comprehensive Cancer Center — Columbus, Ohio, United States
• Vanderbilt University Medical Center — Nashville, Tennessee, United States
• Fred Hutchinson Cancer Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.